NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04892017 2026-04-08Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsDeciphera Pharmaceuticals, LLCPhase 1 Terminated91 enrolled
NCT03340506 2026-04-01Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT02642042 2026-03-04Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting60 enrolled 24 charts